
Consun Pharmaceutical Group Limited
1681.HKHKSEHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
HK$13.28
−HK$0.32 · -2.35%
1681.HK company overview
Regular session · HKT · Market data may be delayed.
Company profile
Company websiteConsun Pharmaceutical Group Limited operates as an investment holding company, primarily engaged in the research, development, manufacturing, and distribution of traditional Chinese medicines and sophisticated medical contrast agents throughout the People's Republic of China. The company's operations are structured into two main divisions: Consun Pharmaceutical and Yulin Pharmaceutical. Consun offers a diverse array of pharmaceutical products. For kidney-related conditions, it provides uremic clearance granule for chronic kidney diseases and Yishen Huashi particles to address proteinuria. In the field of medical imaging, the company supplies Gadopentetate Dimeglumine injections, a contrast medium vital for MRI diagnostics of the central nervous system, abdomen, chest, pelvis, and extremities, alongside assessing renal function. Another key imaging agent is Iopamidol injections, utilized in neuroradiology, angiography, and urography. Its extensive portfolio of traditional Chinese medicines includes Zhixueling capsules, effective in managing various bleeding disorders such as uterine bleeding, prolonged lochia, intermenstrual spotting, post-contraceptive ring bleeding, hemorrhoidal bleeding, and epistaxis. Gyn Antidysmenorrheic tablets are offered to alleviate irregular and painful menstruation, including issues experienced during perimenopause due to hepatic depression and blood deficiency. For feminine hygiene, Antibacterial Fujie lotion combats common vaginal infections caused by Staphylococcus aureus, Candida albicans, and Escherichia coli. The company also markets bone-setting liquid and Yunxiang analgesic tincture for a range of ailments including rheumatism, common colds, headaches, stomachaches, chest pain, gastric pain, and chilblains. Additionally, Sanqi Chuangchun capsules are available to enhance blood circulation and reduce stasis, while Shiduqing capsules, tablets, and Paeonol ointment target various skin conditions. The product line is further rounded out with hepatobiliary, gastroenterology, tonic, and other general medicines. Beyond its traditional Chinese remedies and contrast media, the company also markets pharmaceutical products such as Yuanli Kang, an iron-dextrin oral solution; Yibao Yua, an erythromycin estolate suspension; and Yuantong Ning, a cetirizine hydrochloride oral solution. Established in 1997, Consun Pharmaceutical Group Limited is headquartered in Guangzhou, People's Republic of China.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Headquarters
- CN
- CEO
- Meng An
- Listed since
- Dec 19, 2013
- Employees
- 3,115
Market position
- Volume
- 711K
- 0.46× average
- Average volume
- 1.55M
- Average daily volume
- Market cap
- 11.14B HKD
- Beta
- 0.48
- Market reference 1
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 10.95B CNY
- P/E (TTM)
- 8.96×
- P/B (TTM)
- 2.14×
- P/S (TTM)
- 2.79×
- EV / EBITDA
- 9.07×
- Earnings yield
- 8.97%
- Free cash flow yield
- 9.51%
- Dividend yield
- 5.50%
Profitability & efficiency
- Gross margin
- 78.05%
- Operating margin
- 35.18%
- Net margin
- 31.55%
- Return on equity
- 23.76%
- Return on assets
- 16.81%
- Return on invested capital
- 21.08%
Financial health
- Debt / equity
- 0.05×
- Current ratio
- 3.22×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 3.42B CNY | 2.97B CNY | 2.59B CNY | 2.34B CNY | 2.04B CNY |
| Cost of goods sold | 750.24M CNY | 725.13M CNY | 668.44M CNY | 576.74M CNY | 517.32M CNY |
| Gross profit | 2.67B CNY | 2.24B CNY | 1.92B CNY | 1.76B CNY | 1.53B CNY |
| Research and development | 151.84M CNY | 97.54M CNY | 108.54M CNY | 117.54M CNY | 102.16M CNY |
| Selling, general, and administrative | 1.52B CNY | 1.29B CNY | 1.17B CNY | 1.09B CNY | 900M CNY |
| Operating expenses | 1.46B CNY | 1.2B CNY | 1.04B CNY | 1.01B CNY | 818.57M CNY |
| Interest income | 85.28M CNY | 88.3M CNY | 68.92M CNY | 52.41M CNY | 39.25M CNY |
| Interest expense | 4.36M CNY | 24.89M CNY | 21.26M CNY | 10.93M CNY | 12.91M CNY |
| Depreciation and amortization | 55.61M CNY | 71.58M CNY | 78.09M CNY | 70.48M CNY | 68.53M CNY |
| Operating income | 1.2B CNY | 1.05B CNY | 884.97M CNY | 757.33M CNY | 708.77M CNY |
| Net income | 1.08B CNY | 910.46M CNY | 784.53M CNY | 682.91M CNY | 590.17M CNY |
Company facts updated Aug 24, 2026.
Earnings
- Latest fiscal-year EPS
- 1.26
- FY2025 · +15.60% year over year
- Latest fiscal-year revenue
- 3.42B CNY
- FY2025 · +15.17% year over year
Annual EPS trend
Reported history and fiscal-year consensus
Annual revenue trend
Reported history and fiscal-year consensus
Corporate actions
Annual dividends per share
Cash distributions grouped by calendar year; partial years are marked.
HK$0.63
2025 complete year+250.0% since 2020
2026 partial: HK$0.40
HK$0.18
2,020
HK$0.30
2,021
HK$0.45
2,023
HK$0.90
2,024
HK$0.63
2,025
HK$0.40
2,026*
* Partial calendar year in the available dividend history.
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jun 9, 2026 | HK$0.40Semi-Annual | Jun 10, 2026 | Jun 22, 2026 |
Dividend | Sep 4, 2025 | HK$0.33Semi-Annual | Sep 5, 2025 | Sep 19, 2025 |
Dividend | Jun 10, 2025 | HK$0.30Semi-Annual | Jun 11, 2025 | Jun 20, 2025 |
Dividend | Sep 5, 2024 | HK$0.30Annual | Sep 9, 2024 | Sep 20, 2024 |
Dividend | Jun 11, 2024 | HK$0.60Special | Jun 12, 2024 | Jun 21, 2024 |
Dividend | Sep 7, 2023 | HK$0.15Quarterly | Sep 11, 2023 | Sep 20, 2023 |
Ex-dividend Jun 9, 2026
HK$0.40
Semi-Annual
Record Jun 10, 2026 · Payment Jun 22, 2026
Ex-dividend Sep 4, 2025
HK$0.33
Semi-Annual
Record Sep 5, 2025 · Payment Sep 19, 2025
Ex-dividend Jun 10, 2025
HK$0.30
Semi-Annual
Record Jun 11, 2025 · Payment Jun 20, 2025
Ex-dividend Sep 5, 2024
HK$0.30
Annual
Record Sep 9, 2024 · Payment Sep 20, 2024
Ex-dividend Jun 11, 2024
HK$0.60
Special
Record Jun 12, 2024 · Payment Jun 21, 2024
Ex-dividend Sep 7, 2023
HK$0.15
Quarterly
Record Sep 11, 2023 · Payment Sep 20, 2023
1681.HK peers
ETFs holding 1681.HK
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard FTSE Emerging Markets ETFVWO11.96M0.01%162.3B USD0.06%$60.45+0.72%
Vanguard Total International Stock ETFVXUS11.62M0.00%646.2B USD0.05%$87.71+0.78%
iShares Core MSCI Emerging Markets ETFIEMG9.28M0.01%160B USD0.09%$81.57+0.64%
Cambria Emerging Shareholder Yield ETFEYLD8.56M0.95%902.76M USD0.65%$48.07+0.94%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS3.41M0.02%13.6B USD0.06%$160.06+0.43%
Avantis Emerging Markets Equity ETFAVEM1.75M0.01%27.89B USD0.33%$94.24+0.75%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM599.13K0.01%9.49B USD0.39%$39.93+0.50%
Vanguard Total World Stock ETFVT559.33K0.00%97.9B USD0.06%$160.77+0.53%
Vanguard FTSE Emerging Markets ETFVWO- Market value
- 11.96M
- Weight
- 0.01%
- AUM
- 162.3B USD
- Expense ratio
- 0.06%
- Price / 1D
- $60.45+0.72%
Vanguard Total International Stock ETFVXUS- Market value
- 11.62M
- Weight
- 0.00%
- AUM
- 646.2B USD
- Expense ratio
- 0.05%
- Price / 1D
- $87.71+0.78%
iShares Core MSCI Emerging Markets ETFIEMG- Market value
- 9.28M
- Weight
- 0.01%
- AUM
- 160B USD
- Expense ratio
- 0.09%
- Price / 1D
- $81.57+0.64%
Cambria Emerging Shareholder Yield ETFEYLD- Market value
- 8.56M
- Weight
- 0.95%
- AUM
- 902.76M USD
- Expense ratio
- 0.65%
- Price / 1D
- $48.07+0.94%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS- Market value
- 3.41M
- Weight
- 0.02%
- AUM
- 13.6B USD
- Expense ratio
- 0.06%
- Price / 1D
- $160.06+0.43%
Avantis Emerging Markets Equity ETFAVEM- Market value
- 1.75M
- Weight
- 0.01%
- AUM
- 27.89B USD
- Expense ratio
- 0.33%
- Price / 1D
- $94.24+0.75%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM- Market value
- 599.13K
- Weight
- 0.01%
- AUM
- 9.49B USD
- Expense ratio
- 0.39%
- Price / 1D
- $39.93+0.50%
Vanguard Total World Stock ETFVT- Market value
- 559.33K
- Weight
- 0.00%
- AUM
- 97.9B USD
- Expense ratio
- 0.06%
- Price / 1D
- $160.77+0.53%
Continue in GoAI
Research 1681.HKresearch.disclaimer





